Jnana Therapeutics, a Boston, MA-based biotechnology company, raised $107M in Series C funding.
The round was led by Bain Capital Life Sciences with participation from existing investors including RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures and Pfizer Ventures. Ron Renaud, a Managing Director at Bain Capital Life Sciences, is joining Jnana’s Board of Directors in conjunction with the financing.
The company intends to use the funds to progress its lead program in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and to advance additional wholly owned, potential first-in-class medicines in immune-mediated diseases and cancer.
Led by CEO Joanne Kotz, and President and CSO Joel C. Barrish, Ph.D., Jnana Therapeutics is a clinical-stage biotechnology company leveraging its chemoproteomics platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. The company is focused on developing therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Its wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Jnana’s RAPID chemoproteomics platform enabled the identification of JNT-517, a small-molecule inhibitor of the phenylalanine transporter SLC6A19 that acts at a novel, cryptic allosteric site, as well as a growing pipeline of programs against challenging-to-drug targets such as transcription factors.
FinSMEs
15/11/2022